Vivimed Labs share news, announcements and annual reports
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Vivimed Labs Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2005
Last close ₹5.53down ₹0.11 (1.95%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹5.64.
30 Oct: open ₹5.62, high ₹5.64, low ₹5.53
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹46 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 3,267
Vivimed Labs disputes and clarifications
39 filed, newest first.
Oct 2026
22 Oct · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.
Jul 2026
31 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: The response of the Company is awaited.
Jun 2026
Jan 2026
13 Jan · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.6 Jan · Legal
The exchange asked on 5 Jan 2026
Sep 2025
8 Sep · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
Jul 2025
15 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Jun-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. The response of the Company is awaited.15 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed under Schedule III of the Companies Act, 2013. -2. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Jun 2025
30 Jun · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI -2. Financial results submitted in XBRL with discrepancies The response of the Company is awaited.
Mar 2025
Jun 2023
16 Jun · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2023 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Modified Opinion or in case of unmodified opinion(s), a declaration to that effect to the Stock Exchange. The response of the Company is awaited.
Jan 2022
18 Jan · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated 10-Jan-2022, regarding Resignation of Mrs. Umanath Varahabhotla as Independent Director of the company w.e.f. January 10, 2022. On basis of above the Company is required to clarify following: 1. Confirmation from the resigning director that there are no other material reasons other than provided; 2. The Letter of resignation of the independent director mentioning the detailed reasons for the resignation; 3. Names of listed entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. The response of the Company is awaited.
Apr 2021
23 Apr · Legal
The exchange asked on 22 Apr 2021
Aug 2020
1 Aug · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
Jul 2020
Jun 2020
Apr 2020
13 Apr · Legal
Clarification by Vivimed Labs Limited Significant price movement has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vivimed Labs Limited has vide its letter inter-alia stated, Dear Sir/Madam, we wish to state that in compliance with the requirements of Regulation 30 of theSEBI (LODR) Regulations, 2015, we have regularly intimated to the Exchange, all the events,information etc. that have a bearing on the operations / performance of the Company, whichinclude all price sensitive information. We also wish to confirm that other than what we have already disclosed, from time to time,currently there is no further material event / information, which requires disclosure pursuant to the SEBI (LODR) Regulations, 2015. We trust the above clarifies the matter With RegardsYugandhar KopparthiCompany SecretaryVivimed Labs Ltd9 Apr · Legal
Significant movement in price has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Dec 2019
6 Dec · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Sep-2019 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Statement of Cash Flow not submitted The response of the Company is awaited.
Feb 2019
1 Feb · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated 29-Jan-2019, regarding a press release dated January 29, 2019, titled "SALE OF 50% STAKE IN ITS 50:50 JV TO STRIDES".". On basis of above the Company is required to clarify following: 1. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.2. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";3. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.4. Consideration received from such sale/disposal;5. The expected date of completion of sale/disposal;6. Date on which the agreement for sale has been entered into;7. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;The response of the Company is awaited.
Jan 2019
24 Jan · Legal
The exchange asked on 23 Jan 2019
Aug 2018
17 Aug · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated 13-Aug-2018, regarding " Vivimed Labs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 13, 2018.". On basis of above the Company is required to clarify following: 1. Date of appointment/cessation (as applicable) & term of appointment; 2. Reason for change viz. appointment, resignation, removal, death or otherwise; The response of the Company is awaited.
Jun 2018
4 Jun · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to Non-compliance as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Reconciliation of profit and loss not submitted The response of the Company is awaited.
Apr 2017
20 Apr · Legal
Exchange has sought clarification from the Company with respect to news item captioned "Vivimed Labs Mulls Selling stake in Chennai Formulation plant". In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company is aware of any information that has not been announced to the Exchanges under regulation 30 of Listing Regulations. The response from the Company is awaited.17 Apr · Legal
The exchange asked on 13 Apr 2017
Jan 2017
12 Jan · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated 12-Jan-2017, regarding Outcome of Board Meeting held on January 12, 2017.On basis of above the Company is required to clarify following:1. Reasons for termination.2. Names of the investors;The response of the Company is awaited.
Sep 2016
22 Sep · Legal
The exchange asked on 21 Sep 2016
Jul 2016
25 Jul · Legal
Exchange has sought clarification from Vivimed Labs Limited with respect to announcement dated July 22, 2016, regarding press release dated July 22, 2016 title " Klar Sehen Private Limited, a wholly owned subsidiary of Vivimed announces the sale of certain products along with associated trademarks Total consideration for the identified products and trademarks is Rs. 730 million".On basis of above the Company is required to clarify following:1. The amount and percentage of the turnover or revenue or income and net worth contributed by such products along with associated trademarks during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.5. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length".The response of the Company is awaited.
Aug 2014
5 Aug · Legal
Exchange had sought clarification from Vivimed Labs Limited with respect to a news item captioned "Sebi slaps Rs 10 lakh fine on Vivimed Labs for violation". The Company has clarified that "The company received the order of SEBI on 4th August 2014 for violation of provisions of Clause 20(a) of the Listing Agreement read with Section 21 of the Securities Contracts (Regulation) Act, 1956 (hereinafter referred to as 'SCRA,1956'), Viz., Not intimating the exact date of payment of Dividend/Date of despatch of Dividend warrants (for the financial year 2012-13 ) to the stock Exchanges. SEBI imposed a penalty of Rs.10,00,000/- (Rupees Ten Lakh only) on Vivimed Labs Limited under Section 23E of the SCRA,1956. It has no material impact on its present or future operations or its profitability or its financials".
Jul 2014
Apr 2012
4 Apr · Legal
Vide its letter dated April 04, 2012 regarding "This has reference to reports in a leading business television channel that 'Vivimed Labs Limited' may do placement to Lo'real, the company would like to clarify that said reports are untrue."